BioCentury
ARTICLE | Company News

Cempra, U.S. Department of Health and Human Services infectious news

March 21, 2016 7:00 AM UTC

HHS’s Biomedical Advanced Research and Development Authority (BARDA) exercised an option under a 2013 contract with Cempra to develop solithromycin ( CEM-101) to treat infections in pediatric populations and infections caused by bioterror threat pathogens. Under the latest option segment, Cempra will receive $25.5 million to conduct an international Phase II/III trial to evaluate IV, oral capsule and oral suspension formulations of solithromycin in about 400 patients ages two to 17 with community-acquired bacterial pneumonia (CABP). Cempra plans to begin the trial this half, with full enrollment expected during 1H18.

The initial base contract provided $17.7 million in funding for two years, and Cempra received an additional $16 million in 2014 to fund a Phase Ib trial of solithromycin (see Biocentury, Jan. 12, 2015). ...